Page 221 - DUOKOPT BIBLIOBOOK

EFFICACY

Konstas et al 24-Hour IOP-Lowering Effects of Latanoprost and Dorzolamide/Timolol

timolol on the diurnal intraocular pressure in exfoliation and Morphological changes in the anterior eye segment after
primary open-angle glaucoma. Arch Ophthalmol 1997;115: long-term treatment with different receptor selective prosta-
975–9. glandin agonists and a prostamide. Invest Ophthalmol Vis Sci
13. Book SA. Essentials of Statistics. New York: McGraw-Hill; 2003;44:4419–26.
1978:117–22, 205–15. 20. AGIS Investigators. The Advanced Glaucoma Intervention
14. Konstas AG, Maltezos AC, Gandi S, et al. Comparison of Study (AGIS): 7. The relationship between control of intraoc-
24-hour intraocular pressure reduction with two dosing regi- ular pressure and visual field deterioration. Am J Ophthalmol
mens of latanoprost and timolol maleate in patients with 2000;130:429–40.
primary open-angle glaucoma. Am J Ophthalmol 1999;128: 21. Heijl A, Leske MC, Bengtsson B, et al. Measuring visual field
15–20. progression in the Early Manifest Glaucoma Trial. Acta Oph-
15. Mundorf TK, Cate EA, Sine CS, et al. The safety and efficacy thalmol Scand 2003;81:286–93.
of switching timolol maleate 0.5% solution to timolol hemi- 22. Boger WP III. Shortterm “escape” and longterm “drift”: the
hydrate 0.5% solution given twice daily. J Ocul Pharmacol
Ther 1998;14:129–35. dissipation effects of the beta adrenergic blocking agents. Surv
16. Duff GR. A double-masked crossover study comparing the Ophthalmol 1983;28:235–42.
effects of carteolol 1% and 2% on intra-ocular pressure. Acta 23. Manni G, Centofanti M, Parravano M, et al. A 6-month
Ophthalmol (Copenh) 1987;65:618–21. randomized clinical trial of bimatoprost 0.03% versus the
17. Stewart WC, Day DG, Stewart JA, et al. The efficacy and association of timolol 0.5% and latanoprost 0.005% in glau-
safety of latanoprost 0.005% once daily versus brimonidine comatous patients. Graefes Arch Clin Exp Ophthalmol 2004;
0.2% twice daily in open-angle glaucoma or ocular hyperten- 242:767–70.
sion. Am J Ophthalmol 2001;131:631–5. 24. Zimmerman TJ, Stewart WC, Latanoprost Axis Study Group.
18. Siegel S. Nonparametric Statistics for the Behavioral Sci- Intraocular pressure, safety, and quality of life in glaucoma
ences. New York: McGraw-Hill; 1956:63–7. patients switching to latanoprost from monotherapy treat-
19. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. ments. J Ocul Pharmacol Ther 2003;19:405–15.

103

221